Skip to content

Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)

Clinical Research for Traditional Mongolian Medicine in the treatment of novel coronavirus pneumonia (COVID-19)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030751
Enrollment
Unknown
Registered
2020-03-13
Start date
2020-01-25
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:Traditional Mongolian Medicine

Sponsors

Affiliated Hospital of Inner Mongolia University for the Nationalities
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) novel coronavirus pneumonia novel coronavirus pneumonia is diagnosed according to the new pneumonia diagnosis and treatment plan (trial version fifth); (2) According to the diagnostic standard of "lung invasion" in Mongolian medicine "myxosis", the patients were diagnosed as Mongolian medicine "myxosis" acute fever; (3) RT-PCR was used to detect the new coronavirus in respiratory or blood samples; (4) Aged 18 to 70 years old; (5) subjects' informed consent and signing informed consent.

Exclusion criteria

Exclusion criteria: (1) Other viral pneumonia (influenza virus parainfluenza virus adenovirus respiratory syncytial virus rhinovirus human metapneumovirus SARS Coronavirus) was excluded; (2) Serious mental illness or history of depression; (3) Suspected allergy to any of the following substances or contraindications for the application of any of the following substances include the active ingredients of the test drug and emergency medicine and other ingredients contained in the test drug or emergency medicine; (4) Pregnant and lactating women who plan to be pregnant or cannot use reliable contraceptive measures; (5) Any concomitant disease that may interfere with the procedure or evaluation of the trial or other conditions that the investigator considers unsuitable for inclusion in the trial.

Design outcomes

Primary

MeasureTime frame
nucleic acids probing;blood routine;blood biochemistry;Urine Routine;Blood Gas Analysis;CT;

Countries

China

Contacts

Public ContactBurenbatu

Affilated Hospital of Inner Mongolia University for the Nationalities

nmbrbt8989@163.com+86 18804758989

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026